Puretech Health Stock Price, News & Analysis

Vedanta Biosciences announced the publication of Phase 1a/1b study results for VE303, a bacterial consortium candidate for preventing Clostridium difficile infection, in Cell Host & Microbe. The study showed VE303 was well-tolerated and effectively colonized the gut when dosed over multiple days. Preparations for Phase 3 trials are underway following positive topline Phase 2 results published in 2021, which revealed a 31.7% reduction in CDI recurrence rates. Three abstracts related to VE303 and VE202 will be presented at Digestive Disease Week 2022.

PureTech Health announced that Akili’s AKL-T03 digital therapeutic demonstrated a statistically significant improvement in sustained attention in adults with major depressive disorder (MDD) when combined with antidepressant therapy, as published in the American Journal of Psychiatry. The STARS-MDD trial involved 80 adults and showed a 0.005 significance level. This digital therapeutic builds on the technology of EndeavorRx, already FDA-cleared for treating children with ADHD. Akili aims to fill a gap in treating cognitive impairments associated with depression, a condition affecting over 16 million Americans.

PureTech Health has announced the publication of groundbreaking research demonstrating its Glyph technology, which enhances the oral bioavailability of buprenorphine by up to 20-fold. This technology utilizes lymphatic transport, which bypasses first-pass liver metabolism, significantly improving drug delivery for conditions that require effective opioid replacement therapy. Published in Frontiers in Pharmacology, this study highlights the potential of Glyph technology to revolutionize treatment approaches for various clinically validated drugs.

PureTech Health plans to publish its annual report and financial results on April 26, 2022, at 2:00 AM EDT. This report will detail the financial status as of December 31, 2021, and include the cash balance for Q1 2022. A conference call for discussion will occur on the same day at 9:00 AM EDT. The company aims to highlight progress in its pipeline and its commitment to environmental, social, and governance practices. PureTech is focused on developing treatments for serious diseases and has 25 therapeutic candidates in its pipeline.

PureTech Health announced the appointment of Sharon Barber-Lui as a non-executive director and chair of the Audit Committee. With over 20 years at Merck & Co., Barber-Lui brings extensive experience in finance and operations. She previously led U.S. Oncology Portfolio Market Strategy at Merck and currently serves at EQRx. Her expertise is expected to enhance the board's strategic vision, particularly for PureTech's advanced clinical programs.

PureTech Health announces Jon David as the new Chief Product Officer of its Founded Entity, Akili Interactive. With over 20 years in the gaming industry, David is expected to drive Akili's product pipeline, developing innovative cognitive treatments that feel like high-end entertainment. His leadership experience includes positions at Glu Mobile and PopCap Games, where he contributed to hit franchises. This strategic appointment underscores Akili's commitment to merging entertainment with therapeutic solutions as it prepares for its merger with Social Capital Suvretta Holdings Corp. I.

Gelesis Holdings Inc. (NYSE: GLS) announced promising preliminary results from its media campaign launched on January 31, 2022. Patient prescriptions for Plenity surged 3.5-fold within three weeks, accompanied by a threefold increase in web traffic. Gelesis anticipates $58 million in net revenue for 2022, reinforcing prior guidance. Approximately 4,700 new Plenity members joined weekly, with 70% being new to prescription weight management. Healthcare provider prescriptions doubled since the campaign's inception, showcasing a robust response to the digital-first strategy.

Vedanta Biosciences, a clinical-stage company based in Cambridge, Massachusetts, is pioneering new oral therapies derived from defined bacterial consortia. CEO Bernat Olle, Ph.D., will participate in a panel at the Chardan Metagenomics and Microbiome Medicines Summit on March 1, 2022. The panel, titled 'Great Debate - Is the Term “Microbiome” Drug Development Passé?', is set for 3:15 PM ET, followed by Olle's presentation at 4:30 PM ET. The company focuses on treating high-risk C. difficile infections, inflammatory bowel diseases, and more.